Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07549412 · ClinicalTrials.gov registry record · Phase 3
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
A Phase 3 study, sponsored by EMD Serono Research & Development Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,020
- Enrollment target
NCT07549412: Recruiting Phase 3 study, sponsored by EMD Serono Research & Development Institute.
NCT07549412 is a Phase 3 study that is actively recruiting participants, run by EMD Serono Research & Development Institute. The registered enrollment target is 1,020 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07549412, a Phase 3 study, is actively recruiting participants, sponsored by EMD Serono Research & Development Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,020 participants
- Enrollment target
Study Summary
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
Interventions
- DRUG Bevacizumab
- DRUG Precemtabart tocentecan
- DRUG Trifluridine/Tipiracil (FTD-TPI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2026-05-06 |
| Est. Completion | 2029-10-16 |
| Phase | Phase 3 |
What NCT07549412 shows while recruiting
NCT07549412 is an interventional study that assigns participants to a tested intervention. Its 1,020 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% higher).
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT07549412 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07549412 about?
NCT07549412 is a clinical study titled "A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)". This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) a...
What is the current status of trial NCT07549412?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,020 participants. The study started on 2026-05-06. Estimated completion is 2029-10-16.
What interventions are being tested in trial NCT07549412?
The interventions under investigation include: Bevacizumab (DRUG), Precemtabart tocentecan (DRUG), Trifluridine/Tipiracil (FTD-TPI) (DRUG).
Who is sponsoring clinical trial NCT07549412?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07549412's enrollment target sits among peer trials
1,020 291st of 2000 higher than 1,708 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- NCT05225428 · 1,020 participants · NA
Video Education With Result Dependent dIsclosure
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06760637 · 1,020 participants · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI